COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler, Elisabeth G E de Vries, Corine H GeurtsvanKessel, John B Haanen, Bernhard Wörmann, Samra Turajlic, Marie von Lilienfeld-Toal

Research output: Contribution to journalReview articlepeer-review

134 Citations (Scopus)
69 Downloads (Pure)


Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

Original languageEnglish
Pages (from-to)385–401
Number of pages17
JournalNature Reviews Clinical Oncology
Early online date11-Mar-2022
Publication statusPublished - Jun-2022


Dive into the research topics of 'COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety'. Together they form a unique fingerprint.

Cite this